Total Payments
$884,793
2024 Payments
$86,641
Companies
50
Transactions
957
Medicare Patients
9,431
Medicare Billing
$2.5M
Payment Breakdown by Category
Other$737,861 (83.4%)
Consulting$74,285 (8.4%)
Travel$50,208 (5.7%)
Food & Beverage$17,810 (2.0%)
Research$4,140 (0.5%)
Education$490.23 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $587,828 | 242 | 66.4% |
| Honoraria | $150,033 | 63 | 17.0% |
| Consulting Fee | $74,285 | 42 | 8.4% |
| Travel and Lodging | $50,208 | 188 | 5.7% |
| Food and Beverage | $17,810 | 406 | 2.0% |
| Unspecified | $4,140 | 7 | 0.5% |
| Education | $490.23 | 9 | 0.1% |
Payments by Type
General
$880,653
950 transactions
Research
$4,140
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $120,730 | 84 | $0 (2024) |
| Incyte Corporation | $112,326 | 124 | $0 (2024) |
| Blueprint Medicines Corporation | $99,527 | 94 | $0 (2024) |
| Janssen Biotech, Inc. | $81,103 | 87 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $76,002 | 61 | $0 (2023) |
| ADC Therapeutics America, Inc. | $70,027 | 63 | $0 (2024) |
| Amgen Inc. | $54,172 | 66 | $0 (2020) |
| Celgene Corporation | $52,972 | 58 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $40,907 | 40 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $39,662 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $86,641 | 107 | Blueprint Medicines Corporation ($30,848) |
| 2023 | $133,547 | 189 | Blueprint Medicines Corporation ($46,023) |
| 2022 | $147,033 | 137 | Karyopharm Therapeutics Inc. ($31,578) |
| 2021 | $69,690 | 69 | Kite Pharma, Inc. ($25,753) |
| 2020 | $106,155 | 82 | Karyopharm Therapeutics Inc. ($30,001) |
| 2019 | $108,326 | 112 | Amgen Inc. ($23,684) |
| 2018 | $127,375 | 138 | Incyte Corporation ($55,005) |
| 2017 | $106,026 | 123 | Incyte Corporation ($37,878) |
All Payment Transactions
957 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,283.00 | General |
| 12/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,890.00 | General |
| Category: CELLT | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $5.70 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/10/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $110.30 | General |
| Category: CELLT | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $119.83 | General |
| 11/12/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $4,004.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/05/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/15/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $4,004.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,854.00 | General |
| 09/26/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $115.43 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $132.87 | General |
| 09/04/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $4,620.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/04/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | Cash or cash equivalent | $244.12 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/04/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $7.21 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/29/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $694.40 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/27/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,200.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 1,934 | 25,745 | $1.9M | $447,425 |
| 2022 | 43 | 1,993 | 38,040 | $2.0M | $452,202 |
| 2021 | 57 | 2,711 | 57,115 | $3.4M | $759,026 |
| 2020 | 63 | 2,793 | 53,817 | $3.6M | $840,169 |
Total Patients
9,431
Total Services
174,717
Medicare Billing
$2.5M
Procedure Codes
206
All Medicare Procedures & Services
206 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 28 | 7,600 | $1.0M | $327,398 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 162 | 414 | $152,352 | $37,720 | 24.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 108 | 138 | $97,566 | $14,152 | 14.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 58 | $28,768 | $7,944 | 27.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 35 | 35 | $37,345 | $6,558 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 89 | $22,250 | $5,656 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 185 | 530 | $10,600 | $4,452 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 182 | 511 | $18,396 | $3,858 | 21.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 77 | 158 | $24,806 | $3,636 | 14.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 35 | $12,495 | $3,205 | 25.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 114 | 309 | $19,776 | $3,172 | 16.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 52 | $10,972 | $3,032 | 27.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 39 | 52 | $17,888 | $2,681 | 15.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $10,635 | $2,605 | 24.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 43 | 43 | $35,303 | $2,523 | 7.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 47 | $14,711 | $2,313 | 15.7% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 30 | 134 | $8,040 | $2,178 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $9,040 | $2,000 | 22.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 63 | 119 | $7,140 | $1,590 | 22.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 24 | $5,928 | $1,494 | 25.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 70 | 117 | $12,636 | $1,445 | 11.4% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 25 | 34 | $4,862 | $1,191 | 24.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 27 | $4,347 | $608.34 | 14.0% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 12 | 12 | $8,232 | $596.42 | 7.2% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 53 | 4,900 | $14,700 | $576.52 | 3.9% |
About Dr. Christopher Maisel, MD
Dr. Christopher Maisel, MD is a Hematology & Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275575185.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Maisel, MD has received a total of $884,793 in payments from pharmaceutical and medical device companies, with $86,641 received in 2024. These payments were reported across 957 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($587,828).
As a Medicare-enrolled provider, Maisel has provided services to 9,431 Medicare beneficiaries, totaling 174,717 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 206 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Dallas, TX
- Active Since 06/12/2006
- Last Updated 09/01/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275575185
Products in Payments
- Yescarta (Drug) $103,200
- AYVAKIT (Drug) $99,527
- DARZALEX (Biological) $92,513
- JAKAFI (Drug) $89,368
- XPOVIO (Drug) $76,002
- NINLARO (Drug) $69,143
- Kyprolis (Biological) $44,528
- Revlimid (Drug) $39,352
- Pomalyst (Drug) $34,417
- BLENREP (Biological) $22,195
- Copiktra (Drug) $15,439
- TECVAYLI (Biological) $15,287
- CALQUENCE (Drug) $15,046
- XGEVA (Biological) $8,793
- IMBRUVICA (Drug) $7,473
- Tecartus (Drug) $6,650
- REBLOZYL (Biological) $5,206
- ELREXFIO (Drug) $3,285
- ONUREG (Drug) $3,108
- ICLUSIG (Drug) $2,952
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dallas
Dr. Houston Holmes, M.d, M.D
Hematology & Oncology — Payments: $261,905
Hematology & Oncology $261,905
Dr. Kartik Konduri, Md, MD
Hematology & Oncology — Payments: $253,193
Hematology & Oncology $253,193
Dr. Farrukh Awan, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $184,107
Hematology & Oncology $184,107
Dr. Joanne Blum, M.d, M.D
Hematology & Oncology — Payments: $183,987
Hematology & Oncology $183,987
Joan Schiller, Md, MD
Hematology & Oncology — Payments: $174,115
Hematology & Oncology $174,115
Dr. Carlos Becerra, M.d, M.D
Hematology & Oncology — Payments: $161,287
Hematology & Oncology $161,287